Q2 Earnings Forecast for PMN Issued By HC Wainwright

Promis Neurosciences (NASDAQ:PMN) – Research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Promis Neurosciences in a report released on Monday, July 14th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.22) per share for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Promis Neurosciences’ current full-year earnings is ($0.24) per share. HC Wainwright also issued estimates for Promis Neurosciences’ Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.66) EPS.

Promis Neurosciences (NASDAQ:PMN) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07).

PMN has been the subject of a number of other research reports. Maxim Group began coverage on shares of Promis Neurosciences in a research note on Monday, May 12th. They set a “buy” rating and a $3.00 target price for the company. Guggenheim restated a “buy” rating and set a $6.00 price objective on shares of Promis Neurosciences in a report on Tuesday, April 1st.

Promis Neurosciences Stock Performance

Promis Neurosciences stock opened at $0.45 on Wednesday. The stock has a 50-day simple moving average of $0.49 and a 200 day simple moving average of $0.68. The stock has a market capitalization of $14.71 million, a P/E ratio of -9.00 and a beta of -0.10. Promis Neurosciences has a 52 week low of $0.38 and a 52 week high of $2.22.

Institutional Trading of Promis Neurosciences

An institutional investor recently raised its position in Promis Neurosciences stock. Allostery Investments LP increased its stake in Promis Neurosciences (NASDAQ:PMN) by 19.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 233,703 shares of the company’s stock after purchasing an additional 38,592 shares during the period. Allostery Investments LP owned approximately 0.71% of Promis Neurosciences worth $165,000 as of its most recent filing with the SEC. 50.13% of the stock is owned by institutional investors and hedge funds.

About Promis Neurosciences

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.